Ciprofloxacin for the Treatment of Infections Caused by Carbapenemase-Producing Gram-Negative Bacteria
Rubiñan, Pablo (Complexo Hospitalario Universitario de Vigo)
Viñado, Belén (Hospital Universitari Vall d'Hebron)
Fernández-Hidalgo, Nuria (Universitat Autònoma de Barcelona. Departament de Medicina)
Larrosa, María Nieves (Instituto de Salud Carlos III)
Sempere, Abiu (Hospital Clínic i Provincial de Barcelona)
Campany, David (Hospital Universitari Vall d'Hebron)
Rodriguez-Pardo, Dolors (Universitat Autònoma de Barcelona. Departament de Medicina)
González-López, Juanjo 1975- (Universitat Autònoma de Barcelona. Departament de Medicina)
Nuvials, Xavier (Vall d'Hebron Institut de Recerca (VHIR))
del Barrio-Tofiño, Ester (Hospital Universitari Vall d'Hebron)
Escolà-Vergé, Laura (Institut de Recerca Sant Pau)
Los-Arcos, Ibai (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2024
Abstract:	Background: There is no experience with ciprofloxacin for the treatment of carbapenemase-producing Gram-negative bacteria (CP-GNB) infections. Methods: This is a retrospective single-centre study where we describe the clinical evolution of all consecutive adult patients who received ciprofloxacin monotherapy for the treatment of CP-GNB infections. Primary outcomes were clinical failure (defined as death, lack of clinical improvement or a switch to another drug) at day 14 and 30-day all-cause mortality. Results: Nineteen patients were included. Fifteen (79%) were men, the median age was 74 years (IQR 66-79) and the median Charlson comorbidity index was five (IQR 3-6. 5). The most frequent infections were: nine complicated urinary tract infections, three soft tissue infections and three intra-abdominal infections. Twenty CP-GNBs were isolated (one patient had a coinfection): nine VIM-type-producing Enterobacterales, nine OXA-48-type-producing Enterobacterales and two VIM-type-producing Pseudomonas aeruginosa. Six (32%) patients had positive blood cultures, and one presented with septic shock. The median duration of ciprofloxacin treatment was 14 days (IQR 10-15). One patient presented with clinical failure at day 14. There was no 30-day mortality. Two patients exhibited microbiological recurrence at day 90. There were no reported adverse effects. Conclusions: Monotherapy with ciprofloxacin may be an alternative treatment for selected, clinically stable patients with ciprofloxacin-susceptible CP-GNB infections. CB21/13/00054.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Fluoroquinolones ; OXA ; VIM ; Multidrug-resistant ; Carbapenem-resistant
Published in:	Antibiotics, Vol. 13 (november 2024) , ISSN 2079-6382

DOI: 10.3390/antibiotics13121138
PMID: 39766528

12 p, 490.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles